3-氨基-5,6,7,8-四氢喹啉-2(1H)-酮 | 865855-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 3-氨基-5,6,7,8-四氢喹啉-2(1H)-酮
• 英文名称: 3-amino-5,6,7,8-tetrahydroquinolin-2(1H)-one
• 英文别名: 3-amino-1,2,5,6,7,8-hexahydroquinolin-2-one；3-amino-5,6,7,8-tetrahydro-1H-quinolin-2-one
• CAS: 865855-13-6
• 化学式: C₉H₁₂N₂O
• mdl: MFCD22371785
• 分子量: 164.207
• InChiKey: FBEDPNPNAGUDGK-UHFFFAOYSA-N

物化性质

• 沸点：
  474.6±28.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.444
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-((13S,15R)-4-fluoro-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-15-yl)propanoic acid 、 3-氨基-5,6,7,8-四氢喹啉-2(1H)-酮 在 吡啶 、 三苯基膦 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 以86%的产率得到3-((13S,15R)-4-fluoro-13-methyl-17-oxo-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-15-yl)-N-(2-oxo-1,2,5,6,7,8-hexahydroquinolin-3-yl)propanamide
  参考文献：
  名称：

  [EN] 15.BETA.-[3-PROPANAMIDO]-SUBSTITUTED ESTRA-1,3,5(10)-TRIEN-17-ONE COMPOUNDS AND THEIR 17-OXIMES FOR USE IN INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASES
  [FR] DÉRIVÉS STÉROÏDIENS THÉRAPEUTIQUEMENT ACTIFS

  摘要：

  公开号：

  WO2018224736A3

文献信息

• Synthesis and evaluation of 2-pyridinone derivatives as HIV-1 specific reverse transcriptase inhibitors. 1. Phthalimidoalkyl and -alkylamino analogs
  作者：Jacob M. Hoffman、John S. Wai、Craig M. Thomas、Rhonda B. Levin、Julie A. O'Brien、Mark E. Goldman

  DOI：10.1021/jm00099a006

  日期：1992.10

  A potent (IC50 = 30 nM), specific nonnucleoside HIV-1 reverse transcriptase (RT) inhibitor 3-[N-(phthalimidomethyl)amino]-5-ethyl-6-methylpyridin-2(1H) -one (1), was discovered through an in vitro screening program. This compound did not inhibit (IC50 > 300 microns) other DNA and RNA polymerases, including HIV-2 RT and SIV-RT. Unfortunately, hydrolytic instability of this (aminomethyl)phthalimide precluded

  一种有效的（IC50 = 30 nM）特异性非核苷HIV-1逆转录酶（RT）抑制剂3- [N-（邻苯二甲酰亚胺甲基）氨基] -5-乙基-6-甲基吡啶-2（1H）-一（1）是通过体外筛选程序发现的。该化合物不会抑制（IC50> 300微米）其他DNA和RNA聚合酶，包括HIV-2 RT和SIV-RT。不幸的是，这种（氨基甲基）邻苯二甲酰亚胺的水解不稳定性不能用作抗病毒剂。在本系列的第一篇论文中，描述了初步开发工作，该工作生产了乙基邻苯二甲酰亚胺20，该水解稳定的化合物具有降低的HIV-1 RT抑制活性（100倍）和在H9细胞中的抗病毒活性弱（CIC95 = 40 microM）。结构活性研究表明了5-乙基的重要性，吡啶酮环上的6-甲基取代基图案以及在吡啶酮和邻苯二甲酰亚胺杂环之间需要一个灵活的两个原子的连接基。这些引线1和20为进一步开发这种抑制剂结构类型提供了基础，从中选择了几种化合物（随附报告的主题）进行临床评估。
• [EN] ESTRA-1,3,5(10)-TRIENE COMPOUNDS CONDENSED IN POSITION 16(17) WITH A PYRAZOLE RING AS INHIBITORS OF 17-HSD1<br/>[FR] COMPOSÉS ESTRA-1,3,5(10)-TRIÈNE CONDENSÉS EN POSITION 16(17) AVEC UN CYCLE PYRAZOLE UTILISÉS COMME INHIBITEURS DE LA 17-HSD1
  申请人：FORENDO PHARMA LTD

  公开号：WO2020115371A1

  公开（公告）日：2020-06-11

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent dis-eases or disorders, such as steroid hormone dependent dis-eases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

  该发明涉及式（I）的化合物及其药用盐（I），其中R1至R4如权利要求中所定义。该发明还涉及它们作为17β-HSD1的抑制剂的用途，以及用于治疗或预防类固醇激素依赖性疾病或紊乱，如需要抑制17β-HSD1酶和/或需要降低内源性雌二醇浓度的类固醇激素依赖性疾病或紊乱。本发明还涉及上述化合物的制备以及包含上述化合物或其药用盐作为活性成分的药物组合物。
• 5-amino-5,6,7,8-tetrahydroquinolines and related compounds, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0489379A1

  公开（公告）日：1992-06-10

  The present invention relates to tetrahydroquinolines and related compounds. More particularly, the present invention relates to 5-amino-5,6,7,8-tetrahydroquinolines of the formula wherein X-Y is a group of the formula wherein R is hydrogen, alkyl, alkenyl, alkynyl, or arylalkyl, or a group of the formula wherein R¹ is hydrogen, alkyl or arylalkyl; R² and R³ are independently hydrogen, alkyl, arylalkyl, diarylalkyl, cycloalkenylalkyl, alkoxy, arylalkoxy, or alkanoyl; R² and R³ taken together with the nitrogen atom to which they are attached form a group of the formula wherein p is 0 or 1, a group of the formula wherein Z is O, S, or a group of the formula NR⁶ wherein R⁶ is hydrogen, alkyl, or arylalkyl; R⁴ is hydrogen, alkyl or arylalkyl; R⁵ is hydrogen, alkyl or arylalkyl; and m is 0, 1, or 2, and n is 1 or 2; or geometrical and optical isomers thereof, or a pharmaceutically acceptable salt thereof, which are useful for relieving memory dysfunction, The invention relates further to a process for the preparation of these compounds and their use as medicaments.

  本发明涉及四氢喹啉及相关化合物。更具体地说，本发明涉及式 5-氨基-5,6,7,8-四氢喹啉 其中 X-Y 是式中的基团 其中 R 是氢、烷基、烯基、炔基或芳烷基，或者是式中的基团 其中 R¹ 是氢、烷基或芳基烷基；R² 和 R³ 独立地是氢、烷基、芳基烷基、二芳基烷基、环烯基烷基、烷氧基、芳基烷氧基或烷酰基；R² 和 R³ 与它们所连接的氮原子一起形成式中的基团 式中 p 为 0 或 1 的基团 其中 Z 是 O、S 或式 NR⁶的基团，其中 R⁶ 是氢、烷基或芳基烷基；R⁴ 是氢、烷基或芳基烷基；R⁵ 是氢、烷基或芳基烷基；以及 m 是 0、1 或 2，n 是 1 或 2；或其几何和光学异构体，或其药学上可接受的盐，可用于缓解记忆功能障碍、 本发明还涉及这些化合物的制备工艺及其作为药物的用途。
• Therapeutically active steroidal derivatives
  申请人：FORENDO PHARMA LTD

  公开号：US10717761B2

  公开（公告）日：2020-07-21

  The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone dependent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds or pharmaceutically acceptable salts thereof.

  本发明涉及式（I）化合物及其药学上可接受的盐类 其中 R1 至 R4 如权利要求中定义。本发明进一步涉及它们作为 17β-HSD1 抑制剂和在治疗或预防类固醇激素依赖性疾病或紊乱中的用途，例如需要抑制 17β-HSD1 酶和/或需要降低内源性雌二醇浓度的类固醇激素依赖性疾病或紊乱。本发明还涉及上述化合物的制备，以及包含一种或多种上述化合物或其药学上可接受的盐作为活性成分的药物组合物。
• 3-HETEROATOM SUBSTITUTED CYCLOPENTADIENYL-CONTAINING METAL COMPLEXES AND OLEFIN POLYMERIZATION PROCESS
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0923589A1

  公开（公告）日：1999-06-23